Cardiovascular pharmacology and therapeutics form the backbone of managing heart-related conditions through targeted drug development and clinical applications. Medications like beta-blockers, ACE inhibitors, and antiplatelet agents play a critical role in treating hypertension, heart failure, and coronary artery disease. Advances in this field have led to novel therapeutics, including sodium-glucose cotransporter-2 (SGLT2) inhibitors and PCSK9 inhibitors, which offer new hope for patients with complex cardiovascular conditions. Ongoing research focuses on personalized medicine, exploring how genetic factors influence drug response to optimize treatment strategies. By blending pharmacology with innovative therapies, this field aims to improve cardiovascular outcomes while minimizing side effects.
Title : Pharmacological advancement in pulmonary arterial hypertension treatment - Contribution of treprostinil dry-powder formulation
Miroslav Radenkovic, University of Belgrade, Serbia
Title : Historical evolution from OPCAB to MIDCAB to mini OPCAB surgical technique and results
Federico Benetti, Benetti Foundation, Argentina
Title : Personalized and Precision Medicine (PPM) and PPN-guided cardiology practice as a unique model via translational applications and upgraded business modeling to secure human healthcare, wellness and biosafety
Sergey Suchkov, N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Antibodies with functionality as a new generation of translational tools designed to monitor autoimmune myocarditis at clinical and subclinical stages
Sergey Suchkov, N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation